Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-28
DOI
10.1038/s41598-019-51959-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
- (2018) Eduardo Méndez et al. CLINICAL CANCER RESEARCH
- Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases
- (2017) et al. MOLECULES
- G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1
- (2017) Chia-Jung Busch et al. RADIOTHERAPY AND ONCOLOGY
- Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress
- (2016) Kyle C. Cuneo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
- (2015) N. Tanaka et al. CLINICAL CANCER RESEARCH
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 as a novel therapeutic target for cervical cancer
- (2015) Doo-Yi Oh et al. Oncotarget
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination
- (2012) M Krajewska et al. ONCOGENE
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Targeting Radiation-Induced G2 Checkpoint Activation with the Wee-1 Inhibitor MK-1775 in Glioblastoma Cell Lines
- (2011) B. Sarcar et al. MOLECULAR CANCER THERAPEUTICS
- In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762
- (2010) J. B. Mitchell et al. CLINICAL CANCER RESEARCH
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- Genomewide Gene Expression Profiles of HPV-Positive and HPV-Negative Oropharyngeal Cancer
- (2009) Pawadee Lohavanichbutr et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search